Russia’s COVID-19 Vaccine Being Tested in Volunteers

The World Health Organization data estimates that more than 100 draft vaccines were in development worldwide as of late April

Telesur English

russian vaccine
Men and women between the ages of 18-60 can participate in the trial as long as they are in good health. (Photo taken from themoscowtimes.com/).

Russia’s Ministry of Defense and the National Research Center for Epidemiology and Microbiology Gamaleya announced that the vaccine being developed by both institutions will provide immunity against coronavirus infection for at least two years.

The vaccine will create adenovirus containers, a component necessary for encoding the ‘corona’ protein in the coronavirus. 

“This method is the most rational and effective,” Gamaleya’s director Alexandr Guintburg said.

The vaccine will be administered twice, making it possible to obtain protective immunity for a prolonged period of time.

“A patient will be protected from possible coronavirus infection for at least two years and possibly longer,” Guintburg assured.

This week, specialists began administering the experimental vaccine to a group of volunteers.

The Ministry of Defense announced Russia’s COVID-19 vaccine could begin mass application this fall. 

“Up to 70 million doses of the drug may be required to start mass vaccination of the population against a new coronavirus infection,” Guintsburg said.

Russia’s sanitary authorities have demonstrated the drug’s long-term potential effect. They took into account the same principle as the Ebola vaccines in Guinea.

Leave a Reply

Your email address will not be published. Required fields are marked *